{"id":"NCT01662063","sponsor":"Genentech, Inc.","briefTitle":"A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)","officialTitle":"A Multicenter Open-Label, Long-Term Extension Study of WA22762 and NA25220 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-08","primaryCompletion":"2014-04","completion":"2014-06","firstPosted":"2012-08-10","resultsPosted":"2016-10-12","lastUpdate":"2016-10-12"},"enrollment":218,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Tocilizumab","otherNames":["RoActemra/Actemra"]}],"arms":[{"label":"SC TCZ QW","type":"EXPERIMENTAL"},{"label":"SC TCZ Q2W","type":"EXPERIMENTAL"}],"summary":"This open-label extension study will evaluate the long-term safety and efficacy of SC TCZ in participants with moderate to severe RA who have completed the 97-week WA22762 (NCT01194414) or 96-week NA25220 (NCT01232569) core studies on SC or intravenous (IV) TCZ. Participants will receive TCZ 162 milligrams (mg) SC every week (QW) or every 2 weeks (Q2W) for up to 96 weeks.","primaryOutcome":{"measure":"Number of Participants With at Least One Serious Adverse Event (SAE)","timeFrame":"From Baseline to 8 weeks after last dose; assessed continuously during treatment (up to 96 weeks) and up to 8 weeks after last dose (up to 2 years overall)","effectByArm":[{"arm":"SC TCZ Q2W","deltaMin":4,"sd":null},{"arm":"SC TCZ QW","deltaMin":19,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":11},"locations":{"siteCount":79,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["27747585"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":44},"commonTop":["Upper respiratory tract infection","Sinusitis","Nasopharyngitis","Urinary tract infection","Arthralgia"]}}